The world’s largest private pharmaceutical group has warned Europe risks falling behind the US and China on access to new medicines, as the German company hailed positive trial results of its weight-loss drug.
Shashank Deshpande, chair of Boehringer Ingelheim, criticised Europe’s pricing regime, warning the region risked ceding its leadership in pharmaceutical innovation.
“Europe has a choice. Do we want to continue being a leader in pharmaceuticals or do we also want to yield this industry to the US and especially China, which is rapidly increasing in terms of its pharmaceutical innovation,” he said.
您已阅读17%（606字），剩余83%（3055字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。